ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions
- Acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market
- Outpatient therapy services added to ResMed’s growing SaaS offering portfolio
- Purchase price of €958.6 million (US$997.5 million); deal will be accretive to non-GAAP diluted earnings per share
SAN DIEGO and HILDESHEIM, Germany, Nov. 22, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has completed its €958.6 million acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers.
MEDIFOX DAN is headquartered in Hildesheim, Germany, with over 700 employees. It now operates under its current brand within the ResMed SaaS business segment. Its administrative, financial, and operational solutions are mission-critical for out-of-hospital care providers, providing care documentation, personnel planning, administration, billing, and more – similar to the solutions of ResMed’s leading U.S. SaaS brands, MatrixCare and Brightree.
“We’re excited to have closed this important expansion of our SaaS business, and to officially welcome MEDIFOX DAN to our ResMed SaaS team and global ResMed family,” said ResMed CEO Mick Farrell. “MEDIFOX DAN is a German leader in software innovation, united with the rest of ResMed in its mission to improve tens of millions of people’s lives through technology. Today, its strong offerings and dedicated staff expand ResMed’s out-of-hospital SaaS business into new health sectors, and to build on our strong ResMed healthcare business in Germany, the world’s second largest healthcare market in per capita spending.”
“Starting today, we are continuing our success story as part of the ResMed family,” said MEDIFOX DAN Co-Managing Directors Dr. Thorsten Schliebe and Christian Städtler. “With ResMed, we have found an ideal partner –global leaders in digital health, cloud-based SaaS solutions with emphasis on innovation, data privacy and data security – with which we can continue to grow, develop, and provide our customers with secure, state-of-the-art software solutions and services, so they can navigate the challenges of their daily caregiving routines in the best possible way.”
ResMed intends to retain MEDIFOX DAN’s employees, locations, and business processes. MEDIFOX DAN will report into ResMed SaaS President Bobby Ghoshal.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
About MEDIFOX DAN
The MEDIFOX DAN Group, headquartered in Hildesheim, Germany, currently employs over 700 people at nine locations nationwide and specializes in the development of innovative software solutions and services for professional and non-professional care, therapeutic practices and child, family, and youth welfare facilities. In addition, digital solutions for modern training and education management - both for professional care and family caregivers - expand the group's comprehensive product portfolio. What started as a small start-up developed into a firmly established software company. Besides holistic product solutions, MEDIFOX DAN has always been characterized by strong partnerships and innovative services. Behind MEDIFOX DAN stands a team of innovative minds, over 55 years of industry experience and cumulative expertise, that works every day to set trendsetting standards for digitization in the health and social care sector and to drive innovation forward. In short: We are more than just software.
For media
In Germany: resmedGER@allisonpr.com
Rest of world: Jayme Rubenstein, +1 508.769.8440, news@resmed.com
For investors
Amy Wakeham, +1 858.836.5000, investorrelations@resmed.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders1.5.2024 23:10:26 CEST | Press release
LUXEMBOURG, May 01, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that its annual general meeting of shareholders and its extraordinary general meeting of shareholders, both held on April 30, 2024, approved all resolutions on their agendas. Among other resolutions adopted at the annual general meeting, shareholders acknowledged the Company’s 2023 annual report, containing the consolidated management report and the related management certifications and external auditors’ reports, and the Company’s 2023 annual sustainability report, containing the non-financial statement required by Luxembourg law. The shareholders also approved the consolidated financial statements as of and for the year ended December 31, 2023, and the annual accounts as at December 31, 2023. The annual general meeting also approved an annual dividend of US$0.60 per share (or US$1.20 per ADR), which represents an aggregate sum of approximately US$0.7 billion, and which include
CNH is changing its NYSE ticker symbol to “CNH” on May 201.5.2024 22:30:00 CEST | Press release
Basildon, May 1, 2024 CNH Industrial (NYSE: CNHI) announces that the Company’s common shares listed on the New York Stock Exchange (NYSE) will begin trading under the symbol “CNH” effective Monday, May 20, 2024. This will replace the Company’s current ticker symbol, “CNHI”, marking a return to both our original ticker symbol “CNH” – used until 2013 – and our identity as a leading pureplay provider of equipment, technology and services for agriculture and construction. CNH Industrial N.V. will remain the name of the legal entity. The ticker symbol for the Company’s 3.850% Notes due 2027 will also change from “CNHI 27” to “CNH 27” at the same time. No action is required by the Company's shareholders or bondholders with respect to the ticker symbol changes, as the Company’s common stock and notes will continue to be listed on the NYSE and their CUSIP numbers will remain unchanged. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breakin
Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow1.5.2024 20:48:50 CEST | Press release
GRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform. The Koelis Trinity® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The compact Koelis Trinity® system does not require interfaces with either external ultrasound equipment or external sensors. The versatility of the Trinity platform is enabling Koelis to lead the ongoing paradigm sh
Awilco Drilling Plc: Keppel denied leave to appeal the ruling of the AR2 arbitration tribunal1.5.2024 20:34:14 CEST | Press release
Further to the stock exchange releases of 23 November 2023 and 15 January 2024 from Awilco Drilling PLC ("Awilco Drilling") regarding the termination of the newbuilding contract between Awilco Rig 2 Pte. Ltd. ("AR2") and Keppel FELS Limited ("KFELS") for the construction of a semi-submersible drilling rig, hull number B382. The Company has today received the decision of the High Court refusing Keppel’s application for leave to appeal the award of the AR2 arbitration tribunal. The award is in AR2's favour in an amount of USD 43.0 million plus interest and legal costs. Unless the parties can mutually agree, the tribunal will issue a further award related to interest and costs. We will revert once the award has been received and the amounts of interest and costs have been determined. Aberdeen, 1 May 2024 For further information please contact: Eric Jacobs, CEO of Awilco Drilling PLC Phone: +47 9529 2271 Cathrine Haavind, Investor Relations of Awilco Drilling PLC Phone: +47 9342 8464 Email
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc